Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

OBJECTIVES: Mavrilimumab, a human monoclonal antibody targeting the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor, was evaluated in a phase 2 randomised, double-blind, placebo-controlled study to investigate efficacy and safety in subjects with rheumatoid arthritis (...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Weinblatt, Michael E, McInnes, Iain B, Porter, Duncan, Barbarash, Olga, Vatutin, Mykola, Szombati, Istvan, Esfandiari, Ehsanollah, Sleeman, Matthew A, Kane, Christopher D, Cavet, Guy, Wang, Bing, Godwood, Alex, Magrini, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756523/
https://www.ncbi.nlm.nih.gov/pubmed/23234647
http://dx.doi.org/10.1136/annrheumdis-2012-202450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756523/
https://www.ncbi.nlm.nih.gov/pubmed/23234647
http://dx.doi.org/10.1136/annrheumdis-2012-202450

Ejemplares similares